Drug
Voxilaprevir clinical trials
Also written GS-9857.
- studies test it
- 13
- open now
- 0
- in phase 3
- 2
- first study started
- 2014
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2015 (6)
| Year | Studies |
|---|---|
| 2014 | 2 |
| 2015 | 6 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2022 | 1 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 4
- Phase 2
- 3
- Phase 3
- 2
- Phase 4
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 8 · Other 5
Gilead Sciences (8) · University of Maryland, Baltimore (1) · Johns Hopkins University (1) · University of California, San Francisco (1) · M.D. Anderson Cancer Center (1) · Peking University People's Hospital (1)
Often tested with
Tested in the same studies.
Sofosbuvir (9) · Velpatasvir (9) · Ribavirin (3) · Norgestimate (1) · Ethinyl Estradiol (1) · Ledipasvir, sofosbuvir drug combination (1) · Bevacizumab (1) · Atezolizumab (1)
Studies
Open first, then newest update. How each study uses voxilaprevir is read from its arms, and is right about nine times in ten.
Testing it · 13
- Improving Response to Immunotherapy in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C Virus Infection With Direct-Acting Antiviral TherapyTerminatedPhase 4M.D. Anderson Cancer CenterNCT05717400Written as Voxilaprevir
- Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated CirrhosisStatus unknownPhase 4Peking University People's HospitalNCT05467826Written as Sofosbuvir/Velpatasvir/Voxilaprevir
- Safety, Tolerability and Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir in Subjects With Previous DAA ExperienceCompletedPhase 2University of Maryland, BaltimoreNCT02745535Written as Sofosbuvir/Velpatasvir/Voxilaprevir
- deLIVER: Direct Acting Antiviral Effects on the LiverCompletedPhase 4Johns Hopkins UniversityNCT02938013Written as Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]
- Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney TransplantCompletedPhase 4University of California, San FranciscoNCT03619837Written as Sofosbuvir/Velpatasvir/Voxilaprevir
- Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus InfectionCompletedPhase 1Gilead SciencesNCT02185794Written as Voxilaprevir
- Study to Evaluate Effect of Sofosbuvir/Velpatasvir/GS-9857 Fixed-Dose Combination on the Pharmacokinetics of a Representative Hormonal Contraceptive Medication, Norgestimate/Ethinyl EstradiolCompletedPhase 1Gilead SciencesNCT02533427Written as VOX
- Pharmacokinetics of Voxilaprevir in Adults With Normal Hepatic Function and Moderate or Severe Hepatic ImpairmentCompletedPhase 1Gilead SciencesNCT02397707Written as Voxilaprevir
- Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal ImpairmentCompletedPhase 1Gilead SciencesNCT02402452Written as Voxilaprevir
- Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Non-Genotype 1 HCV InfectionCompletedPhase 2Gilead SciencesNCT02378961Written as VOX
- Safety and Efficacy of SOF/VEL/VOX FDC for 8 Weeks and SOF/VEL for 12 Weeks in Adults Chronic Genotype 3 HCV Infection and CirrhosisCompletedPhase 3Gilead SciencesNCT02639338Written as SOF/VEL/VOX
- Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir and Sofosbuvir/Velpatasvir in Adults With Chronic HCV Infection Who Have Not Previously Received Treatment With Direct-Acting Antiviral TherapyCompletedPhase 3Gilead SciencesNCT02607800Written as SOF/VEL/VOX
- Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV InfectionCompletedPhase 2Gilead SciencesNCT02202980Written as VOX
Given in every arm · 2 — voxilaprevir is usual care beside what is tested
- Safety and Efficacy of Voxilaprevir Plus Sofosbuvir/Velpatasvir Fixed Dose Combination in Adults With Chronic Genotype 1 HCV InfectionCompletedPhase 2Gilead SciencesNCT02378935Written as VOX
- Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination With or Without Ribavirin in Participants With Chronic Genotype 1 HCV Infection Previously Treated With a Direct Acting Antiviral RegimenCompletedPhase 2Gilead SciencesNCT02536313Written as SOF/VEL/VOX
Codes
What other systems call voxilaprevir · ClinicalTrials.gg INT000683
- MeSH (NLM) C000619503voxilaprevirOne source NLM
- UNII (FDA) 0570F37359VOXILAPREVIRConfirmed FDA, NLM, Wikidata
- RxNorm 1939323Confirmed FDA, Wikidata
- Wikidata Q27236086voxilaprevirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152922VoxilaprevirOne source FDA
- DrugBank DB12026One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000619503 | voxilaprevir | One source NLM |
| UNII (FDA) | 0570F37359 | VOXILAPREVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 1939323 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27236086 | voxilaprevir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152922 | Voxilaprevir | One source FDA |
| DrugBank | DB12026 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.